ISPOR is strongly committed to diversity. The Society’s Strategic Plan and core values embrace excellence through encouragement and acceptance of diverse ideas, cultures, and disciplines. Workshop submissions are encouraged from all stakeholders and are evaluated based on merit. ISPOR also aims to reflect the diversity of its membership in all endeavors and encourages consideration of diversity in abstract submissions. Diversity dimensions include (but not limited to) gender, career stage, ethnicity, race, education, sexual orientation, region/geographic location, physical disability, and religion. Additional information can be found at the Society’s  Diversity Policy.

  • ISPOR workshops are designed to share novel and innovative experiences in either the conduct of pharmacoeconomics and outcomes research studies or the interpretation and use of pharmacoeconomics outcomes information in health care policy development.
  • An ISPOR workshop is similar to a one-hour short course with an audience participation element.
  • Standard and advanced methods topics workshop submissions follow the same review process.
  • Example of a breakout session proposal submission is available here (downloadable PDF).


Workshop submissions should be organized as follows:


  • Acknowledgments: Submitting authors/submitters must agree to read and agree to ISPOR submission guidelines, ISPOR being an in-person only event, to incorporate audience interactive elements, and AI-Assisted Content Disclosure.
  • Interactive Element: Provide all interactive elements you plan to utilize in your session.
  • Title: Provide a title that accurately describes your breakout session. The title should be in title case, 225 character limit (including spaces). Examples:
    • Fixing the Tower of Babel: Establishing a Common Metric for Patient-Reported Outcome Measures
    • Optimal Allocation of Resources in Managing Medical Device Portfolios
    • Adjusting for Between-Trial Differences in the Schedule of Assessment for Disease Progression in Immuno-oncology and Its Impact on Indirect Treatment Comparisons
  • Submitter Email
  • ISPOR Guidance on the Use of AI-Assisted Technologies in Content: ISPOR has implemented guidance on the use of artificial intelligence (AI) and AI-assisted technologies in submission to the Society’s conferences. Submitting authors/submitters are required to disclose the use of AI and AI-assisted technologies in their submitted abstract(s) and/or accepted materials. Standard word processing spelling and grammar checks do not need to be disclosed. 
  • Joint Clinical Assessment/Scientific Advice in the EU Related Content: Given the ongoing development of the Joint Clinical Assessment process in the EU and the accompanying methods guidance, we anticipate that this will be a highly relevant topic at ISPOR. Similarly, Joint Scientific Consultations constitute an integral part of the EU HTA regulation and provide an opportunity to discuss the development plan to generate evidence to meet the needs of both regulators and HTA bodies with regards to pharmaceuticals and medical devices. Sessions specifically relevant to either the process or methods involved in these areas, especially the more controversial aspects, will be highlighted in our program.
  • RWE Related Content: All topics are welcome, but we also encourage the submission around the topic of real-world evidence.
  • Indicate if Submitter or Authors are Member(s) of an ISPOR Chapter
  • Level of Difficulty: Indicate if this session is Introductory, Intermediate, or Advanced in nature.


Select the taxonomy/topic that best describes your session.

Clinical Outcomes

Clinician Reported Outcomes

Comparative Effectiveness or Efficacy

Performance-based Outcomes

Clinician Outcomes Assessment

Relating Intermediate to Long-term Outcomes

Economic Evaluation

Cost/Cost of Illness/Resource Use Studies

Cost-comparison/effectiveness/utility/benefit Analysis

Budget Impact Analysis

Thresholds & Opportunity Cost

Trial-based economic evaluation

Work & Home Productivity - Indirect Costs

Value of Information

Novel & Social Elements of Value

Epidemiology & Public Health

Safety & Pharmacoepidemiology

Public Health

Prevalence, Incidence, & Disease Risk Factors

Disease Classification & Coding

Health Policy & Regulatory

Approval & Labeling

Pricing Policy & Schemes

Reimbursement & Access Policy

Insurance Systems & National Health Care

Public Spending & National Health Expenditures

Procurement Systems

Coverage with Evidence Development & Adaptive Pathways

Risk-sharing Approaches

Health Disparities & Equity

Health Service Delivery & Process of Care

Hospital and Clinical Practices

Prescribing Behavior

Pharmacist Interventions and Practices

Formulary Development


Quality of Care Measurement

Disease Management

Treatment Patterns and Guidelines

Health Technology Assessment

Systems & Structure

Value Frameworks & Dossier Format

Decision & Deliberative Processes

Medical Technologies

Medical Devices

Digital Health

Diagnostics & Imaging

Implementation Science

Methodological & Statistical Research

Artificial Intelligence, Machine Learning, Predictive Analytics

Missing Data

Confounding, Selection Bias Correction, Causal Inference

Modeling & Simulation

PRO & Related Methods

Survey Methods

Organizational Practices

Academic & Educational



Best Research Practices

Geographic & Regional

Patient-Centered Research

Adherence, Persistence, & Compliance

Stated Preference & Patient Satisfaction

Health State Utilities

Patient-reported Outcomes & Quality of Life Outcomes

Patient Behavior and Incentives

Patient Engagement

Instrument Development, Validation, & Translation

Real World Data & Information Systems

Data Protection, Integrity, & Quality Assurance

Health & Insurance Records Systems

Distributed Data & Research Networks

Reproducibility & Replicability

Study Approaches

Clinical Trials

Pragmatic Trials & Large Simple Trials

Prospective Observational Studies 

Electronic Medical & Health Records


Administrative Claims Data

Surveys & Expert Panels

Decision Modeling & Simulation

Literature Review & Synthesis

Meta-analysis & Indirect Comparisons


What geographical region is this content about?


A workshop is comprised of a Discussion Leader and a minimum of 2 and a maximum of 3 discussants. All discussion leaders and discussants will be asked to provide any previous, relevant speaking/publication experience.

  • Discussion Leaders maintain communication with discussants and ISPOR staff regarding the development and delivery of the session.
  • Amongst the Discussion Leader and Discussants, a diversity of stakeholders, work environments and/or geographic locations is strongly encouraged to provide different perspectives on the topic.
  • Only 2 discussants  per organization is permitted
  • Provide the names, degrees, work environment, affiliation, city, state, country, and email addresses for the discussants.
  • You will be asked for full submitter information on this step as well. The submitter can be the same as an already listed participant.


  • Length of Proposal (Purpose and Description): 300 words
    • Purpose: Provide a clear definition of the workshop’s objective. (Ensure that the purpose(s) is achievable in 60 minutes.)
    • Description: Provide a clear description of the topic including background information & audience participation
      • The audience interactive element is an important criterion to fulfill. Here are examples:
      • Example 1: Each speaker will present a schematic of how patient preference data are included in their respective regulatory processes. The audience will participate in the evaluation exercise drawing on the pros versus cons of each arrangement to develop an ‘ideal’ process for using this data in healthcare decision making.
      • Example 2: The workshop will use real-time polling to work through the examples and conclude with an audience discussion about the opportunities and challenges of using these different methods for portfolio selection.
      • Example 3: The discussion leaders will conduct a real-time test of the validity of audience members’ preferences and help the audience evaluate the implications of such validity failures for regulatory decision making.


  • Review your submission and complete the “Final Steps” acknowledgement form at the bottom. You must complete this final step and select “Conclude Submission,” otherwise your submission will be considered incomplete and not submitted for review. Please note: you will need to complete this step every time you update your submission.


    Overall, workshop acceptance is based on the quality of the proposal and the topic’s importance for inclusion and discussion in this conference’s scientific program. Standard and advanced methods topics workshop submissions follow the same review process.

    Please consider the updated submission criteria when submitting your proposal:

    Quality of content

    • Educational value of the session
    • Timeliness of the topic
    • Applicability of content to HEOR practice or principles
    • Effectiveness of incorporated active learning strategies
    • The information/issue presented are novel or innovative
    • Workshop proposals includes examples drawn from multiple sources
    • Unbiased content that does not promote a product, service, or organization; abstracts deemed to be promotional will be excluded from consideration

    Quality of proposal

    • Plans for interactivity between the speakers and audience
    • Proposal purpose/issue is clearly defined
    • Issue panel proposals have more than one perspective identified
    • The background information (included in the overview) is clear and concise

    Quality of Speakers

    • Expertise/experience of proposed speakers
    • Proposed speakers represent diverse backgrounds (gender, geographic, institutional - refer to ISPOR Diversity policy) and perspectives (multiple organizations are represented)
    Your browser is out-of-date

    ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now